IMGN(Delisted)
ImmunoGenยทNASDAQ
--
--(--)
IMGN Profile
Immunogen, Inc.
A leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer
830 Winter Street, Waltham, MA 02451
--
ImmunoGen, Inc., formed in Massachusetts in 1981, focuses on the development of antibody-based anti-cancer therapies. The company utilizes its
Proprietary antibody-drug conjugation technology and ADC technology for the treatment of cancer. ADC technology contains an antibody that, once the ADC binds to the target, attaches to the cancer cell, binding one of its powerful anticancer agents as a "payload" to kill the cancer cell. ADC is an expanded approach to treating cancer, with two approved treatments and a doubling of the number of agents compared to the past five years.
